Aktienanalyse zu Xoma Royalty Corp (XOMA)XOMAXoma Royalty Corp

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169. It operates in the Consumer Cyclicals sector (PHARMACEUTICAL PREPARATIONS industry).

Xoma Royalty Corp (XOMA) is not a good buy for a beginner investor with a long-term strategy at this time. The pending acquisition by Ligand Pharmaceuticals at $39 per share in cash limits the upside potential, and the stock is trading slightly above this price. There are no significant trading signals or positive catalysts to justify an investment.

3 analysts cover XOMA: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 71.00.